Related Experiment Video
Updated: Dec 20, 2025

CD Spectroscopy to Study DNA-Protein Interactions
Published on: February 10, 2022
Nucleolin represses transcription of the androgen receptor gene through a G-quadruplex
Cindy K Miranti1,2, Sara Moore3, Yongeun Kim4
1University of Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA.
Abstract:
The androgen receptor (AR) is a major driver of prostate cancer development and progression. Men who develop advanced prostate cancer often have long-term cancer control when treated with androgen-deprivation therapies (ADT). Still, their disease inevitably becomes resistant to ADT and progresses to castration-resistant prostate cancer (CRPC). ADT involves potent competitive AR antagonists and androgen synthesis inhibitors. Resistance to these types of treatments emerges, primarily through the maintenance of AR signaling by ligand-independent activation mechanisms. There is a need to find better ways to block AR to overcome CRPC. In the findings reported here, we demonstrate that the nuclear scaffold protein, nucleolin (NCL), suppresses the expression of AR. NCL binds to a G-rich region in the AR promoter that forms a G-quadruplex (G4) structure. Binding of NCL to this G4-element is required for NCL to suppress AR expression, specifically in AR-expressing tumor cells. Compounds that stabilize G4 structures require NCL to associate with the G4-element of the AR promoter in order to decrease AR expression. A newly discovered G4 compound that suppresses AR expression demonstrates selective killing of AR-expressing tumor cells, including CRPC lines. Our findings raise the significant possibility that G4-stabilizing drugs can be used to increase NCL transcriptional repressor activity to block AR expression in prostate cancer. Our studies contribute to a clearer understanding of the mechanisms that control AR expression, which could be exploited to overcome CRPC.
Insights
Nuclear nucleolin (NCL) suppresses androgen receptor (AR) expression by binding to a G-quadruplex (G4) in the AR promoter. G4-stabilizing compounds, with NCL, selectively kill prostate cancer cells, offering new CRPC treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Androgen receptor (AR) signaling drives prostate cancer, but resistance to androgen-deprivation therapies (ADT) leads to castration-resistant prostate cancer (CRPC).
- Current ADT strategies involve AR antagonists and androgen synthesis inhibitors, yet resistance often arises from AR signaling maintained by ligand-independent mechanisms.
- Novel therapeutic approaches are crucial to overcome CRPC by effectively blocking AR signaling.
Purpose of the Study:
- To investigate the role of the nuclear scaffold protein nucleolin (NCL) in regulating AR expression.
- To explore the potential of G-quadruplex (G4) structures and stabilizing compounds as a therapeutic strategy against AR-driven prostate cancer.
Main Methods:
- Assessed NCL's interaction with the AR promoter using G-quadruplex (G4) binding assays.
- Investigated the effect of NCL binding on AR gene expression in AR-expressing tumor cells.
- Evaluated the efficacy of a novel G4 compound in suppressing AR expression and inducing cell death in CRPC models.
Main Results:
- Demonstrated that nucleolin (NCL) directly suppresses androgen receptor (AR) expression by binding to a G-quadruplex (G4) structure in the AR promoter.
- Confirmed that NCL's binding to the AR promoter's G4-element is essential for suppressing AR expression in AR-positive tumor cells.
- Showed that G4-stabilizing compounds, in conjunction with NCL, effectively decrease AR expression and selectively kill AR-expressing cancer cells, including CRPC lines.
Conclusions:
- Nucleolin (NCL) acts as a transcriptional repressor of the androgen receptor (AR) via G-quadruplex (G4) interactions.
- G4-stabilizing drugs represent a promising therapeutic avenue for CRPC by enhancing NCL's ability to suppress AR expression.
- Targeting the NCL-G4-AR interaction could provide a novel strategy to overcome resistance in advanced prostate cancer.
More Related Videos
Related Concept Videos
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Co-activators and Co-repressors
Regulation of Nuclear Protein Sorting
RNA Polymerase II Accessory Proteins
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
The Nucleolus

